期刊
EPILEPSIA
卷 52, 期 -, 页码 76-78出版社
WILEY-BLACKWELL
DOI: 10.1111/j.1528-1167.2011.03008.x
关键词
Recombinant; Patch-clamp; Dravet syndrome
资金
- Biocodex Pharmaceuticals
- NIH-NINDS [RO1-NS045950]
P>The anticonvulsant stiripentol (Diacomittm) has been shown to have a positive impact on control of seizures for many patients with Dravet syndrome. As with most antiepileptic drugs, stiripentol has multiple mechanisms of action. Its direct anticonvulsant activity is likely due to enhancement of inhibitory, gamma-aminobutyric acid (GABA)ergic neurotransmission. Stiripentol was shown to increase the activity of both neuronal and recombinant GABA(A) receptors at clinically relevant concentrations. At recombinant receptors, stiripentol was found to act through a unique site in a subunit-dependent manner. Positive modulation by stiripentol was most effective at GABA(A) receptors containing an alpha 3 subunit. The expression of the alpha 3 subunit is developmentally regulated, with highest levels in the immature brain. This subunit selectivity may explain the greater clinical efficacy of stiripentol in childhood-onset epilepsies, including Dravet syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据